In the BioHarmony Drug Report Database

"Preview" Icon

Aripiprazole lauroxil

Aristada, Abilify (aripiprazole lauroxil) is a small molecule pharmaceutical. Aripiprazole lauroxil was first approved as Aristada on 2004-06-04. It is used to treat schizophrenia and schizophrenia spectrum and other psychotic disorders in the USA. It has been approved in Europe to treat bipolar disorder and schizophrenia. The pharmaceutical is active against D(2) dopamine receptor. In addition, it is known to target 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 6, D(4) dopamine receptor, 5-hydroxytryptamine receptor 7, histamine H1 receptor, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 1B, and 5-hydroxytryptamine receptor 1D. Aristada’s patents are valid until 2035-09-08 (FDA).


Trade Name


Abilify, Abilify Maintena

Common Name


aripiprazole lauroxil






bipolar disorder, schizophrenia, schizophrenia spectrum and other psychotic disorders

Drug Class


Antiulcer agents (benzimidazole derivatives)

Image (chem structure or protein)

Aripiprazole lauroxil structure rendering